PGHH - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.1
| Stock Code | PGHH | Market Cap | 31,123 Cr. | Current Price | 9,580 ₹ | High / Low | 14,540 ₹ |
| Stock P/E | 36.2 | Book Value | 287 ₹ | Dividend Yield | 1.77 % | ROCE | 104 % |
| ROE | 75.7 % | Face Value | 10.0 ₹ | DMA 50 | 10,166 ₹ | DMA 200 | 11,781 ₹ |
| Chg in FII Hold | -0.09 % | Chg in DII Hold | -0.07 % | PAT Qtr | 301 Cr. | PAT Prev Qtr | 210 Cr. |
| RSI | 36.7 | MACD | -140 | Volume | 19,480 | Avg Vol 1Wk | 12,031 |
| Low price | 8,979 ₹ | High price | 14,540 ₹ | PEG Ratio | -43.1 | Debt to equity | 0.00 |
| 52w Index | 10.8 % | Qtr Profit Var | 12.2 % | EPS | 265 ₹ | Industry PE | 44.0 |
📊 Financial Overview: PGHH (Procter & Gamble Hygiene & Health Care) demonstrates exceptional return metrics with ROCE at 104% and ROE at 75.7%, supported by zero debt-to-equity. Quarterly PAT rose from ₹210 Cr. to ₹301 Cr. (12.2% growth), reflecting strong profitability. EPS of ₹265 is robust, and cash flows remain healthy due to debt-free operations. However, revenue growth is modest, and margins are under pressure from high valuations.
💰 Valuation Indicators: Current P/E of 36.2 is below the industry average of 44.0, suggesting fair valuation. P/B ratio of ~33.4 (₹9,580 / ₹287) indicates premium pricing. PEG ratio of -43.1 highlights valuation distortion due to slower earnings growth. Intrinsic value appears close to current price, offering limited margin of safety but strong fundamentals support stability.
🏢 Business Model & Competitive Advantage: PGHH operates in consumer healthcare and hygiene products, benefiting from strong brand equity and demand resilience. Its competitive advantage lies in global brand strength, debt-free balance sheet, and high return ratios. Defensive business model ensures stability even in volatile markets.
📈 Entry Zone & Holding Guidance: Attractive entry zone lies between ₹9,000–₹9,300 (near recent lows and DMA 200 support). Long-term investors may hold for consistent dividends and strong fundamentals. Fresh entry is reasonable at lower levels for defensive portfolio allocation.
Positive
- 🌟 Exceptional [ROCE](ca://s?q=Explain_ROCE) at 104% and [ROE](ca://s?q=Explain_ROE) at 75.7%
- 📈 Debt-free balance sheet ensures financial safety
- 💡 Strong brand presence in healthcare and hygiene
- 💰 Dividend yield of 1.77% adds investor appeal
Limitation
- ⚠️ High [P/B ratio](ca://s?q=Explain_P/B_ratio) of ~33.4
- 📉 PEG ratio negative, indicating valuation distortion
- 🔎 Limited upside due to fair valuation
Company Negative News
- 📉 Decline in FII holdings (-0.09%) and DII holdings (-0.07%)
- ⚠️ Slower revenue growth compared to peers
Company Positive News
- 📈 Quarterly PAT growth of 12.2%
- 💡 Strong brand equity and debt-free operations
Industry
🏭 The FMCG and healthcare industry in India trades at an average P/E of 44.0. PGHH’s P/E of 36.2 suggests fair valuation relative to peers. Industry growth is supported by rising healthcare awareness and hygiene demand, making PGHH well-positioned.
Conclusion
✅ PGHH offers exceptional return metrics, debt-free stability, and strong brand positioning. While valuations are premium, fundamentals remain solid. Entry around ₹9,000–₹9,300 provides a favorable risk-reward balance. Long-term holding is suitable for defensive investors seeking consistent returns and dividend income.
Would you like me to extend this with a FMCG sector outlook or a peer comparison to add more depth?